Skip to Main Content

Rise and shine, another busy day is on the way. We can tell because our short person is, once again, hunched over a laptop for a day of learning and our official mascot is perched by a window waiting for a friend to arrive in what feels like an endless parade of doggie playdates. As for us, we are doing the usual thing — brewing cups of stimulation. Our choice today is vanilla caramel cream. One can never be too sweet, yes? Meanwhile, here are a few items of interest for you. Hope your day goes well and you stay safe. …

The U.K.  is seeking constructive engagement with the U.S. and other World Trade Organization members on the issue of intellectual property waivers for Covid-19 vaccines, Reuters reports. The Biden administration last week threw its support behind waiving intellectual property rights for the vaccines, in a sharp reversal of the previous U.S. position. The U.K. has not joined the U.S. in its position, and a U.K. government spokesman suggested that a waiver alone would not be sufficient to help the situation.


The Food and Drug Administration agreed to let adolescents between the ages of 12 and 15 be vaccinated with the Pfizer (PFE) and BioNTech (BNTX) Covid-19 vaccine, making it the first shot available in the U.S. for use in children under 16, STAT notes. The decision was based on a Phase 3 trial showing the vaccine was safe and effective in the age group. Last month, the companies applied to the European Medicines Agency for a similar expansion of eligibility, and last week, Health Canada expanded its emergency use provision to include adolescents aged 12 to 15.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!